Atrium Therapeutics, Inc. (RNA)

Atrium Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023
Period Ending	Oct 19, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Debt / Equity Ratio	0.01	-0.06	-0.11	-0.14
Debt / FCF Ratio	-	-	-	0.18
Net Debt / Equity Ratio	-1.22	-0.06	-0.11	-0.14
Net Debt / EBITDA Ratio	3.83	-0.07	-0.52	-1.58
Net Debt / FCF Ratio	4.64	-0.09	-0.30	0.18
Asset Turnover	-	2.40	1.25	-
Quick Ratio	8.38	0.00	-	0.02
Current Ratio	8.73	0.07	0.02	0.03
Return on Assets (ROA)	-	-399.25%	-94.53%	-
Return on Capital Employed (ROCE)	-27.80%	148.40%	67.40%	27.20%

Data Source: S&P Global Market Intelligence Last updated: Aug 13, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 19, 2026

Data Sources Report a data error